CRVSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:35):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...

Stats
本日の出来高	60 223.00
平均出来高	199 637
時価総額	73.56M
EPS	$0 ( 2024-03-26 )
次の収益日	( $-0.120 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.68
ATR14	$0.0180 (1.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Arcara Jeffrey	Buy	400 000	Stock Option (Right to Buy)
2024-02-02	Arcara Jeffrey	Buy	0
2023-12-06	Miller Richard A Md	Buy	500 000	Stock Option (Right to Buy)
2023-12-06	Lea Leiv	Buy	200 000	Stock Option (Right to Buy)
2023-12-06	Jones William Benton	Buy	200 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 8 310 910 \| Sell: 8 757 350

ボリューム相関

長: -0.25 (neutral)

短: -0.16 (neutral)

Signal:(50.724) Neutral

Corvus Pharmaceuticals 相関

10 最も正の相関
GNLN	0.95
VTGN	0.947
AQST	0.943
LIXT	0.936
OMCL	0.924
FLGC	0.921
BBLG	0.92
NNOX	0.917
NERV	0.914
APTO	0.914

10 最も負の相関
PRAA	-0.957
PEBK	-0.95
IEP	-0.931
LEXX	-0.928
FOXF	-0.927
CRWS	-0.916
PROV	-0.911
FARO	-0.911
VORB	-0.91
PINC	-0.909

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Corvus Pharmaceuticals 相関 - 通貨/商品

0.50
( neutral )

-0.11
( neutral )

0.00
( neutral )

0.42
( neutral )

-0.33
( neutral )

-0.53
( weak negative )

Corvus Pharmaceuticals 財務諸表

Annual	2023
収益:	$0
総利益:	$-151 000 (0.00 %)
EPS:	$-0.560

FY	2023
収益:	$0
総利益:	$-151 000 (0.00 %)
EPS:	$-0.560

FY	2022
収益:	$0
総利益:	$-367 000 (0.00 %)
EPS:	$-1.080

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.030

Financial Reports:

No articles found.

Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.